Movano Health Q2 2024 operating loss narrows to $6.4M; Evie Ring back in stock Sept 17

Corvex, Inc.

2024-Q2 EPS reported -$0.15 revenue$852,000

Operating loss of $6.4M improved from $7.4M in Q2 2023; no revenue reported as refunds offset deferred revenue.
Shipped 1,837 Evie Rings in Q2; cash and equivalents $16.9M at June 30, 2024.
Evie Ring expected back in stock September 17, 2024; brand partnership with Heidi D'Amelio announced.
FDA live meeting scheduled mid-August for EvieMED 510(k) clearance; B2B opportunities with pharma and payor advancing.
April 2024 $24.1M private placement closed with tier-1 medical device company investment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.